AIP
IOVA icon

Arrowpoint Investment Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Arrowpoint Investment Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,760
Closed -$69.4K – 148
2026
Q1 		$69.4K Buy
+19,760
New +$63.2K 0.06% 76

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Arrowpoint Investment Partners's IOVA Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 19,760 shares — an estimated $69.4K sold.

Arrowpoint Investment Partners first reported a position in IOVA in Q1 2026 and held it in 1 quarter. The position peaked at $69.4K in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 19,760 Iovance Biotherapeutics shares in Q2 2026, an estimated $69.4K.
  • Arrowpoint Investment Partners first reported a position in Iovance Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Iovance Biotherapeutics position peaked at $69.4K in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.